Exscientia : March Corporate Presentation

Precision

Designed.

Personalised

Medicine.

March 2024

Forward-looking Statements

This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forward-looking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operations, future financial position, projected costs, prospects, plans, potential market and growth opportunities, competitive position, market trends, addressable market opportunity and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "target," "potential," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

Forward-looking statements speak only as of the date of this presentation, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events, except as required by applicable law. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the Securities and Exchange Commission ("SEC") after the date of this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

This presentation contains estimates, projections and other information concerning our industry, our business and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are responsible for the accuracy of such information and believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.

2

Patient-firstAI: Integrated technologies to discover, design and develop precision medicines

Encoding & Automating

Accelerated learning to enable more efficient design of higher quality molecules

Precision Medicine

End-to-end patient focused approach to help increase probability of success

Internal Pipeline

Oncology pipeline focused on differentiation and best-in-class opportunities

Partnerships

Collaborations with partners provide both financial and strategic value

CDK7	LSD1	MALT1	Multiple	PKC-theta
			Discovery
			Programmes

3

Delivering better pipeline candidates, faster

8	6	1st
Precision designed	Projects in-licensed	Prospective clinical trial showing
development candidates	by partners	improvement in cancer treatment
		outcomes through AI*

70%	80%	~$4b
Reduction in discovery time	Improved capital efficiency	In pre-commercial milestone potential
from target ID to candidate	in drug discovery

*Kornauth et al. Cancer Discovery 2021

4

4 ways we can improve probability of success

Industry Problem	vs	Exscientia Solution

1

Drug Design

2

Target Biology

3

Patient Selection

4

Clinical Trial Design

Advancing development candidates with known design flaws

Pursuing targets with weak target- disease association

Heterogeneity of disease not captured in preclinical models used to predict patient response

Efficacy often obscured due to protocol issues

Using AI-based multiparameter optimisation to precision design better quality drugs

Create model systems that more closely match actual disease biology

Use of complex heterogeneous primary samples to identify patients most likely to respond to therapy

Use of MIDD and adaptive trial design to identify signals at the earliest timepoint

MIDD = Model-informed Drug Development

5

2023: Positioned us well for long-term growth

Internal Pipeline

• ELUCIDATE Phase 1/2 trial for CDK7 inhibitor (GTAEXS617) initiated in 1Q 2023
• EXS74539 (LSD1 inhibitor) & EXS73565 (MALT1 inhibitor) announced as new wholly owned development candidates
• New preclinical data for LSD1 and MALT1 inhibitors presented at ESMO in October 2023

Precision Medicine

• EXCYTE-1initiated in July 2023: Expanding the scope of precision medicine platform into solid tumours (ovarian cancer)
• Presented data supporting pipeline programmes' potential combination and patient selection strategies at multiple medical meetings in 2023

Partnered Programmes

• AI drug discovery collaboration with Merck KGaA, Darmstadt, Germany signed in September 2023
• New programme internally discovered by Exscientia added to Sanofi collaboration in 4Q 2023
• First milestone achieved in Sanofi collaboration in 3Q 2023
• Phase 1 study for EXS4318, a PKC-theta inhibitor designed by Exscientia and in-licensed by Bristol Myers Squibb, was initiated in March 2023

Technology Updates

• Presented data on automated kinase method to be applied at scale in future projects in 2H 2023
• Novel automated discovery laboratory opened in Milton Park in mid-2023

6

Advancing multiple programmes in 2024

2024

PIPELINE

PARTNERS PLATFORM

• Multiple internal and partnered clinical programmes ongoing with potential for data
• CDK7: Continue enrolling patients in ELUCIDATE Phase 1/2
• LSD1: Clinical study start expected in 2024
• MALT1: Update on programme next steps in 1H 2024
• Additional pipeline updates across internal and partnered programmes
• Precision medicine: Continued clinical evaluation of predictive drug response capabilities; advancement of platform in solid tumours
• Automation: Ramp up of productivity in automation facility
• Advancement of partnered programmes and potential milestone payments
• New business development collaborations expected in 2024

7

Exscientia's solution: Integrating knowledge of

the patient and drug

Intelligent	Proprietary
Clinical Design	Data Generation

Patient-derived	Precision Medicine	Target
Biomarkers		Identification

Model-based	To	Generative AI
come
Learning		Design

8

Why are our clinical candidates different?

Differentiated through design and personalised medicine

Target	Phase	Target Market	Key Differentiation
CDK7	Phase 1/2	Multiple relapsed/refractory solid	Precision designed PK/PD specific for mechanism;
tumour indications	Identification of high-grade responders
PKC-theta	Phase 1	Multiple immunology indications	Better selectivity, improvements in whole blood
potency and low predicted human dose

LSD1	IND-enabling	AML, SCLC and potential additional
indications

Optimised therapeutic index by combining reversibility with short-half life, as well as brain penetration to meet high patient need

MALT1	IND-enabling	Multiple haematology indications	Solved potential dose-limiting toxicity issue present in
competitor compounds

Does not include Exscientia-designed programmes that entered clinical trials through DSP collaboration;	9
AML = acute myeloid leukaemia; SCLC = small-cell lung cancer

Pursuing high quality, differentiated medicines

Precision designed pipeline to fulfill patient unmet needs

						IND-				PIVOTAL/
PROGRAMME		TARGET (INDICATION)		DISCOVERY		ENABLING		PHASE 1/2		APPROVED

GTAEXS617	CDK7		Co-owned (GTA)
	(Advanced Solid Tumours)

EXS4318	PKC-theta		Milestones & Royalties (BMY)
	(Inflammatory Diseases)
EXS74539	LSD1		Wholly Owned
	(AML, SCLC)
EXS73565	MALT1		Wholly Owned
	(Haematology)
Multiple			Wholly Owned/
Discovery
Programmes			Partnerships

Multi-target

collaborations with

Sanofi, BMY and

Merck KGaA

Broad internal

focus on precision

oncology

Additional clinical

programmes through

DSP collaboration

PKC-theta is in a Phase 1 healthy volunteer (HV) study;	10
AML = acute myeloid leukaemia; SCLC = small-cell lung cancer